GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AIM ImmunoTech
AIM ImmunoTech is a biotech company developing immunomodulatory drugs. Its stock price is highly volatile, reflecting the long history of clinical trials of its lead drug, Ampligen, for the treatment of various diseases, from cancer to chronic fatigue syndrome.
Share prices of companies in the market segment - Pharma immune
AIM ImmunoTech is a biopharmaceutical company developing drugs to treat immune disorders, viral diseases, and various types of cancer. We've classified it in the Pharma: Immunology category. The chart below shows how investors value companies working in immune system activation.
Broad Market Index - GURU.Markets
AIM ImmunoTech is a biopharmaceutical company developing drugs to treat cancer and viral diseases by modulating the immune system. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how AIM compares to it.
Change in the price of a company, segment, and market as a whole per day
AIM - Daily change in the company's share price AIM ImmunoTech
The daily fluctuations of AIM ImmunoTech Inc. shares reflect the extreme volatility inherent in biotech companies. This metric measures the sensitivity to news about clinical trials of its immunomodulatory drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
AIM ImmunoTech develops drugs to treat immune disorders, viruses, and cancer. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess AIM stock performance in the context of the overall industry.
Daily change in the price of a broad market stock, index - GURU.Markets
AIM ImmunoTech is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AIM ImmunoTech
For AIM ImmunoTech Inc., the year-to-date performance is the story of its drug, Ampligen. Its 12-month market cap is extremely volatile and depends on news from its numerous clinical trials, where the drug is being studied for various types of cancer, chronic fatigue syndrome, and "long" COVID.
Annual dynamics of market capitalization of the market segment - Pharma immune
AIM ImmunoTech is a biopharmaceutical company developing immunomodulators for the treatment of viral diseases and cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AIM ImmunoTech, a biopharmaceutical company developing drugs to treat immune disorders, cancer, and viral diseases, operates at the forefront of immunology. Its annual market capitalization dynamics, compared to the market, are highly sensitive to clinical trial results. The success of a single drug can lead to a multifold increase in value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company developing immunomodulators. Its monthly performance is entirely dependent on the results of its numerous clinical trials in oncology and viral diseases. News from any program can trigger a strong reaction.
Monthly dynamics of market capitalization of the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases, including Ampligen. The company has a long history of research. Its success depends on obtaining final approvals and commercialization. The immunopharmaceutical sector chart reflects the overall interest in this field, which is used to evaluate AIM's prospects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
AIM ImmunoTech develops drugs to treat immune diseases, viruses, and cancer. Its shares are highly volatile and driven by news of clinical trials. Interest in the company can spike during pandemics or news of breakthroughs in immunology, making its performance independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AIM ImmunoTech
AIM ImmunoTech develops drugs to treat immune disorders, cancer, and viral diseases. Its weekly stock performance is a classic biotech story: the price moves not with the market, but with news about the clinical trials of its key drug, Ampligen.
Weekly dynamics of market capitalization of the market segment - Pharma immune
AIM ImmunoTech develops drugs to treat immune diseases, cancer, and viral infections. Its shares can react sharply to clinical trial results. The chart allows us to separate the impact of AIM-specific news from general trends observed in the biotech sector as a whole.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
AIM ImmunoTech is a biotech company developing drugs to treat immune diseases and cancer. Its shares are driven by news of clinical trials. The chart will show how their performance is uncorrelated with overall market trends and sentiment.
Market capitalization of the company, segment and market as a whole
AIM - Market capitalization of the company AIM ImmunoTech
ImmunoTech's AIM market capitalization chart reflects investor valuation of its flagship drug, Ampligen. Its dynamics reflect the company's years-long efforts to prove the efficacy of this immunomodulator in treating chronic fatigue syndrome, cancer, and viral diseases. Its low price reflects market skepticism after a long history of mixed results.
AIM - Share of the company's market capitalization AIM ImmunoTech within the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its market share in the pharmaceutical sector is small, but it is based on years of research on its key drug, Ampligen. Its market capitalization reflects both its current use and its potential in combination with other therapies.
Market capitalization of the market segment - Pharma immune
This chart shows the overall value of the entire biotech sector specializing in immune therapy. For AIM ImmunoTech, with its drug Ampligen, this line represents the battle against viruses and cancer. The chart's rise reflects investors' belief that modulating the immune system is the key to treating the most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
AIM ImmunoTech develops immune system modulation drugs for the treatment of cancer and viral diseases. Its market capitalization is the valuation of its key drug, Ampligen. This represents the market share of the overall company's efforts to "tune" the immune system to fight disease.
Book value capitalization of the company, segment and market as a whole
AIM - Book value capitalization of the company AIM ImmunoTech
AIM ImmunoTech develops drugs to treat immune diseases, cancer, and viral infections. Its book value is its financial resources and the stock of Ampligen. This is its capital for conducting numerous clinical trials. How has it changed? The chart below shows this history.
AIM - Share of the company's book capitalization AIM ImmunoTech within the market segment - Pharma immune
AIM ImmunoTech develops drugs to treat immune disorders and cancer. Its flagship drug, Ampligen, requires manufacturing infrastructure, which constitutes a significant portion of its tangible assets. The chart shows the company's share of the physical infrastructure needed to manufacture immunomodulatory drugs.
Market segment balance sheet capitalization - Pharma immune
AIM ImmunoTech is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. AIM focuses on drug development, and its capital is intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
AIM ImmunoTech's assets are not factories, but primarily intellectual property and inventories of Ampligen, an immunomodulator being studied for the treatment of various cancers and viral diseases. The book value reflects the potential of this unique asset.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company developing drugs to modulate the immune system. Its market capitalization reflects investor valuation of its leading drug for the treatment of various diseases, from cancer to viral infections.
Market to book capitalization ratio in a market segment - Pharma immune
AIM ImmunoTech develops drugs to treat immune disorders, viruses, and cancer. Its valuation on this chart reflects its key drug, Ampligen, and its potential in various therapeutic areas, creating a diversified but risky profile.
Market to book capitalization ratio for the market as a whole
AIM ImmunoTech develops drugs to treat immune diseases and cancer. The company's market value is based on the potential of its lead drug, Ampligen. This chart shows how investors value biotech companies with a single key product that could either make billions or fail.
Debts of the company, segment and market as a whole
AIM - Company debts AIM ImmunoTech
AIM ImmunoTech, a biopharmaceutical company developing immunomodulators, funds its numerous clinical trials for various diseases with raised capital. This chart illustrates its strategy for testing the potential of its lead drug across a wide range of applications, which requires significant financial resources.
Market segment debts - Pharma immune
AIM ImmunoTech is a biopharmaceutical company developing drugs to treat immune disorders, viral diseases, and cancer. Its key drug, Ampligen, is being studied for multiple applications. The chart shows how the company funds its numerous and diverse clinical programs, a challenging task for a small company.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AIM ImmunoTech
AIM ImmunoTech develops drugs for the treatment of immune disorders, viral diseases, and cancer, including Ampligen. Lengthy clinical trials and the regulatory approval process require significant investment. This chart illustrates the company's reliance on debt to fund its costly research.
Market segment debt to market segment book capitalization - Pharma immune
AIM ImmunoTech develops drugs that modulate the immune system to treat cancer and viral diseases. Immunotherapy is one of the most expensive areas in pharmaceuticals. This chart shows how the company finances its clinical trials. It relates its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
AIM ImmunoTech develops drugs to treat immune disorders, viral diseases, and cancer. Biotechnology requires massive investments in clinical trials with a high risk of failure. How heavily is the company reliant on debt? This graph of total debt in the economy helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company developing treatments for immune disorders, viral diseases, and cancer, based on its drug Ampligen. This chart shows how investors view its multi-year efforts to find a successful application for its core asset.
P/E of the market segment - Pharma immune
AIM ImmunoTech is an immunopharmaceutical company developing and commercializing therapeutics for the treatment of immune disorders, viral diseases, and various types of cancer. Its flagship drug is Ampligen. This chart illustrates the average valuation in the immunopharmaceutical sector, where investors are betting on drugs that modulate the immune system.
P/E of the market as a whole
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders, viral diseases, and various types of cancer. Its flagship drug is Ampligen. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether AIM's valuation is based on confidence in the potential of its drugs or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AIM ImmunoTech
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its key drug, Ampligen, is being studied in various therapeutic areas. This chart shows how much investors believe in the potential of this molecule and its ability to gain approval for the treatment of serious diseases, which shapes the company's valuation.
%20P%2FE%20AIM%20ImmunoTech&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AIM-ImmunoTech&v=1772567350129 "Chart of the company's future (projected) P/E AIM ImmunoTech")
Future (projected) P/E of the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its flagship drug, Ampligen, is being studied for various indications. The chart reflects future profit forecasts for the sector, helping to understand how much investors believe in the broad therapeutic potential of this unique drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772567350211 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
AIM ImmunoTech develops immunomodulatory drugs for the treatment of viral diseases and cancer. The company is exploring a wide range of applications for its key drug. This chart of overall risk appetite in the biotech sector shows how willing investors are to invest in platform drugs with multiple potential, but not always proven, applications.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567350233 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company whose key drug is an immunomodulator being studied for the treatment of various cancers and viral diseases. Financial indicators reflect the costs of numerous clinical trials. This chart shows investments in exploring the potential of a single drug across a wide range of therapeutic areas.
Profit of companies in the market segment - Pharma immune
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders, viral diseases, and cancer. Its key drug is aimed at modulating the immune system. This chart shows the overall profitability of the immunopharmaceutical sector, where the ability to "tune" the body's immune response is key to treating many diseases.
Overall market profit
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Like most biotech companies, its success depends on the results of clinical trials. This process is independent of the general economic cycles shown in the chart, as the need to treat serious diseases is always pressing.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AIM ImmunoTech
AIM ImmunoTech develops immunomodulatory drugs for the treatment of various types of cancer and viral diseases. Future profits depend on the results of numerous clinical trials the company is conducting with its key drug, Ampligen. This chart shows analyst expectations regarding the potential of this unique drug.
%20profit%20of%20the%20company%20AIM%20ImmunoTech&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AIM-ImmunoTech&v=1772567350318 "Graph of future (projected) profit of the company AIM ImmunoTech")
Future (predicted) profit of companies in the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of various cancers and viral diseases. Its key drug, Ampligen, is being studied in multiple clinical trials. This chart shows revenue forecasts for the immunopharmaceuticals sector, providing context for assessing the broad potential of the AIM platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772567350329 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its prospects depend on the success of clinical trials. This economic outlook affects the overall investment climate in the biotech sector, which influences the funding of companies like AIM.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567350350 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AIM ImmunoTech
AIM ImmunoTech develops immunomodulatory drugs for the treatment of various diseases, including cancer and viral infections. Revenue from its key drug, Ampligen, is a key metric. This chart shows how investors view current sales and the company's significant potential for expanding indications.
P/S market segment - Pharma immune
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat cancer and viral diseases. Its lead drug, Ampligen, is an immune system modulator that may enhance the effectiveness of other treatments. This chart reflects the average revenue estimate for the sector, helping to gauge the market's perception of the AIM platform's potential.
P/S of the market as a whole
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders, viral diseases, and cancer. This chart highlights that the valuation of such companies is based on the potential of their drugs to change the standard of care, which justifies high multiples even with modest or nonexistent revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AIM ImmunoTech
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat cancer and viral diseases by modulating the immune system. Its flagship drug is Ampligen. Its revenue valuation is important to the company. It reflects investor expectations for the drug's success in numerous clinical trials and its potential as part of a combination therapy.
%20P%2FS%20AIM%20ImmunoTech&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AIM-ImmunoTech&v=1772567350503 "The graph of the company's future (projected) P/S AIM ImmunoTech")
Future (projected) P/S of the market segment - Pharma immune
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders, viral diseases, and cancer. Its flagship drug is Ampligen. This chart shows how investors estimate the company's future revenue compared to the pharmaceutical sector. It demonstrates the market's confidence in Ampligen's therapeutic potential and its potential application across various diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772567350572 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
AIM ImmunoTech develops immunomodulatory drugs, such as Ampligen, for the treatment of cancer and viral diseases, including "long COVID." The company's future depends on the results of clinical trials. This chart of overall market expectations reflects investor belief that modulating the immune system is key to treating many diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567350603 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AIM ImmunoTech
This chart shows AIM ImmunoTech's revenue from sales of its drug Ampligen, as well as income from grants and partnerships. The company develops immunomodulatory drugs for the treatment of cancer and viral diseases. This growth reflects both commercial and research progress.
Sales of companies in the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its lead drug, Ampligen, generates some sales revenue, but its main potential lies in its development in combination with other treatments. The revenue breakdown shows current sales and potential for future approvals.
Overall market sales
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. The company's success depends on the results of clinical trials of its lead drug, Ampligen. This general economic performance chart does not reflect the company's prospects, which are determined solely by medical research and clinical practice.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AIM ImmunoTech
AIM ImmunoTech is an immunopharmaceutical company developing treatments for immune disorders, viral diseases, and cancer. Its flagship drug is Ampligen. Revenue growth depends on the expansion of this drug and the success of its other developments. This chart shows analyst sales forecasts, reflecting their views on the potential of immunotherapy.
%20sales%20of%20the%20company%20AIM%20ImmunoTech&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AIM-ImmunoTech&v=1772567350778 "Schedule of future (projected) sales of the company AIM ImmunoTech")
Future (projected) sales of companies in the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. This chart shows the outlook for the immunotherapy sector. Do analysts expect new approaches to "tuning" the immune system to drive overall market growth? This helps assess the overall scientific and commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772567350835 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
AIM ImmunoTech is an immunopharmaceutical company developing drugs for the treatment of cancer and viral diseases. Its prospects depend on the results of clinical trials and regulatory approval. The overall economic trends reflected in this chart do not impact patient demand for innovative treatments for serious diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567350880 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company developing immunomodulatory drugs for the treatment of cancer and viral diseases, including its key drug, Ampligen. This chart shows its extensive clinical development pipeline. Profitability depends on regulatory approval for new indications for its drug, which could open significant commercial opportunities.
Market segment marginality - Pharma immune
AIM ImmunoTech Inc. is an immunopharmaceutical company developing drugs for the treatment of cancer and viral diseases. Its flagship drug, Ampligen, is in multiple clinical trials. This chart reflects the company's financial position, whose profitability depends on the success of these trials and regulatory approval for widespread use.
Market marginality as a whole
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. The company operates at the intersection of several medical fields. This overall profitability chart reflects the investment climate in the biotech sector, which determines the availability of capital for conducting expensive clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company whose drug Ampligen is being studied for the treatment of various cancers and viral diseases. Its small team coordinates numerous clinical trials. This diagram shows the compact structure that manages a vast and complex R&D program, collaborating with research centers.
Share of the company's employees AIM ImmunoTech within the market segment - Pharma immune
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders, viral diseases, and cancer. Its activities are focused on clinical research. This chart shows the company's share of the biotech labor market, which is an indicator of the scale of its clinical programs and the size of its scientific team.
Number of employees in the market segment - Pharma immune
AIM ImmunoTech develops immunomodulatory drugs for the treatment of cancer and viral diseases. Its key drug, Ampligen, stimulates the immune system to fight pathogens and abnormal cells. The chart illustrates employment in the immunopharmaceutical sector. AIM's approach involves activating the body's own immune system.
Number of employees in the market as a whole
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat cancer and viral diseases. Its activities are driven by scientific research and clinical trials. This chart shows general trends, but AIM represents a sector where employment is not dependent on the economy, but rather a direct investment in health and disease control.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AIM ImmunoTech (AIM)
AIM ImmunoTech is a biotech company known for its drug Ampligen, which is being studied for the treatment of various immune diseases and cancer. This chart shows how the market values their key asset. It reflects the market value per employee, which is a measure of the value of their IP and the potential of Ampligen.
%20of%20the%20company%20AIM%20ImmunoTech%20(AIM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AIM-ImmunoTech-AIM&v=1772567351228 "Chart of market capitalization per employee (in thousands of dollars) of the company AIM ImmunoTech (AIM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
AIM ImmunoTech (AIM) is an immunopharmaceutical company developing drugs for the treatment of cancer and viral diseases. In this industry, the market capitalization per employee is a measure of the potential of their key drug, Ampligen. Sharp changes in the chart may be related to news about clinical trials, which determine the company's future value.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772567351240 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
AIM ImmunoTech is a biopharmaceutical company developing drugs to treat immune diseases, viral infections, and cancer. Its value is driven by the potential of its key drug, Ampligen. The chart shows a high valuation per employee, as the market is pricing in potential success in several major therapeutic areas.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567351286 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AIM ImmunoTech (AIM)
AIM ImmunoTech is a biotech company developing drugs to treat immune disorders, viruses, and cancer (such as Ampligen). This chart shows how close the company is to commercialization. It reflects how much profit (or loss) the R&D and management teams generate from their drugs at various stages of testing.
%20Chart%20AIM%20ImmunoTech%20(AIM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AIM-ImmunoTech-AIM&v=1772567351300 "Company Profit Per Employee (in thousands of dollars) Chart AIM ImmunoTech (AIM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
AIM ImmunoTech Inc. is an immunopharmaceutical company developing drugs for the treatment of cancer and viral diseases. In this field, a team's effectiveness is determined by its ability to bring promising molecules to clinical use. This chart shows the financial return per employee, which is an indicator of the potential of their developments.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772567351309 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
AIM ImmunoTech is a biotech company developing immunomodulators (such as Ampligen) for the treatment of cancer and viral diseases. It's an R&D company. This chart, showing average market efficiency, provides context for evaluating the biotech model: there's no mass production; all value is created by the intellectual labor of a small group of scientists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567351321 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AIM ImmunoTech (AIM)
AIM ImmunoTech is an immunopharmaceutical company developing drugs to treat immune disorders and cancer. While this metric may be low during the R&D phase, its potential growth, should Ampligen be successful, will reflect the enormous value created by the small scientific and commercial team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AIM-ImmunoTech-AIM&v=1772567351337 "Sales chart per company employee AIM ImmunoTech (AIM)")
Sales per employee in the market segment - Pharma immune
AIM ImmunoTech is a biotech focused on immunology. Their flagship drug is Ampligen, an immune system modulator being studied for the treatment of cancer and chronic fatigue syndrome. This chart shows the average output for the sector. For AIM, this is an indicator of how productive their R&D and commercial teams (if they have sales) are.
Sales per employee for the market as a whole
AIM ImmunoTech is a biotech company developing immune system modulation drugs for the treatment of cancer and viral diseases. Their flagship drug is Ampligen. This chart reflects their R&D status: the company is investing in numerous clinical trials, and sales revenue is currently minimal.
Short shares by company, segment and market as a whole
Shares shorted by company AIM ImmunoTech (AIM)
AIM ImmunoTech (AIM) develops drugs to treat immune disorders, viruses, and cancer, including chronic fatigue syndrome. This chart shows the number of short positions. The short positions may be related to the company's long history of failing to bring a blockbuster to market and skepticism about its current developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AIM-ImmunoTech-AIM&v=1772567351395 "Short Shares Chart for the Company AIM ImmunoTech (AIM)")
Shares shorted by market segment - Pharma immune
AIM ImmunoTech (AIM) is a biopharmaceutical company specializing in immunomodulators, specifically Ampligen, a drug for the treatment of chronic fatigue syndrome and cancer. This chart shows the total short position in the immunopharmaceutical sector. It reflects investor concerns about intense competition and the risks of clinical trials.
Shares shorted by the overall market
AIM ImmunoTech (AIM) is a clinical-stage biotech company. Its value is based on future expectations. When this indicator of market fear rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like AIM in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AIM ImmunoTech (AIM)
AIM ImmunoTech (AIM) develops immunomodulatory drugs, such as Ampligen, for the treatment of cancer and viral diseases, including "long COVID." This oscillator measures momentum. It shows when shares are "overheated" (above 70) on trial news or "oversold" (below 30) due to lack of progress or capital dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AIM-ImmunoTech-AIM&v=1772567351481 "RSI 14 indicator chart for the company's stock AIM ImmunoTech (AIM)")
RSI 14 Market Segment - Pharma immune
AIM ImmunoTech is a biopharmaceutical company known for its Ampligen, an immunomodulator being studied for the treatment of chronic fatigue syndrome and various types of cancer. This chart measures the overall momentum of the immunology biotech sector. It clearly shows when this entire niche is overhyped or oversold.
RSI 14 for the overall market
AIM ImmunoTech (AIM) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AIM (AIM ImmunoTech)
AIM ImmunoTech is a biopharmaceutical company whose key drug (Ampligen) is an immunomodulator. It is being tested for the treatment of "long COVID," chronic fatigue syndrome, and cancer. This chart shows the speculative average price target from analysts, based on their belief in the success of at least one of these clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AIM-AIM-ImmunoTech&v=1772567351557 "A chart showing analyst consensus forecasts for the expected stock price. AIM (AIM ImmunoTech)")
The difference between the consensus estimate and the actual stock price AIM (AIM ImmunoTech)
AIM ImmunoTech is a biotech company whose drug (Ampligen) is an immunomodulator that "turns on" immunity against cancer and viruses (including "long COVID"). This chart shows how much the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AIM-AIM-ImmunoTech&v=1772567351565 "A chart showing the difference between the consensus forecast and the actual stock price. AIM (AIM ImmunoTech)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
AIM ImmunoTech (AIM) is a biotech company developing Ampligen (an immunomodulator) for the treatment of chronic fatigue syndrome (ME/CFS) and "long COVID." This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe R&D can succeed in this challenging market.
Analysts' consensus forecast for the overall market share price
AIM ImmunoTech is a biotech company whose key drug is Ampligen, an immune modulator they are exploring for use in the treatment of cancer, COVID-19, and chronic fatigue syndrome. This chart reflects the overall market "risk appetite." For AIM, a company with a "forever" drug still in development, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AIM ImmunoTech
AIM ImmunoTech is a biotech veteran. Their entire company is built around a single, very old drug (Ampligen)—an immunomodulator that they've been trying unsuccessfully for decades to get approved for chronic fatigue syndrome (CFS) and Long-COVID. This chart is a summary of their perpetual R&D focus. It reflects their cash burn and their (low) chances of FDA approval.
AKIMA Market Segment Index - Pharma immune
AIM ImmunoTech (AIM) is essentially a one-drug company, Ampligen (Rintoleran). It's an immunomodulator they're testing against a wide range of complex diseases, from cancer and long-term COVID to chronic fatigue syndrome (ME/CFS). This chart shows the segment's average index, helping to assess how this risky but diversified R&D strategy compares to the industry average.
The AKIM Index for the overall market
AIM ImmunoTech is an immunopharmaceutical company focused on developing Ampligen, a drug for the treatment of cancer, viral diseases, and immune disorders. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this long-term story with a unique asset compares to overall trends.
